Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Polyphor AG

Spexis to Present at BioEquity Europe 2022
From Polyphor AG
Via AccessWire
Spexis Annual General Meeting 2022
From Polyphor AG
Via AccessWire
Exposures COVID-19
Spexis Publishes Invitation to Annual General Meeting 2022
From Polyphor AG
Via AccessWire
Exposures COVID-19
Spexis Provides Business Update and Announces Financial Results for the Full-Year 2021
From Polyphor AG
Via AccessWire
Spexis to Present Strategy Update and Full-Year 2021 Financial Results on March 24, 2022
From Polyphor AG
Via AccessWire
Topics Earnings
Exposures Financial
Spexis Achieves First CARB-X Milestone for its Thanatin Derivatives Program and Receives Funding of up to USD 1.9 Million to Initiate Lead Optimization
From Polyphor AG
Via AccessWire
Topics Derivatives
Exposures Derivatives
Polyphor Closes Merger with EnBiotix and is Renamed Spexis
From Polyphor AG
Via AccessWire
Polyphor to Inform about the Financing of its Merger Partner EnBiotix
From Polyphor AG
Via AccessWire
Polyphor and EnBiotix Announce Dosing of First Patient in a First-in-Human Clinical Trial of Inhaled Murepavadin
From Polyphor AG
Via AccessWire
Polyphor Shareholders Approve All Resolutions for the Planned Merger with EnBiotix at the Extraordinary General Meeting
From Polyphor AG
Via AccessWire
Topics Bonds
Exposures COVID-19 Debt Markets
Polyphor Publishes Invitation to Extraordinary General Meeting and Announces Financial Results for the First Half 2021
From Polyphor AG
Via AccessWire
Exposures COVID-19
Polyphor and EnBiotix Announce Signing of Merger Agreement and Sale of Inhaled Murepavadin to EnBiotix
From Polyphor AG
Via AccessWire
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.